These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

511 related articles for article (PubMed ID: 34435337)

  • 21. Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital.
    Pannier J; Nass N; Yaakoub MK; Stelzner FMM; Veit S; Kalomoiri M; Yassine M; Behre G
    Infect Dis Rep; 2023 Feb; 15(1):125-131. PubMed ID: 36826353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of COVID vaccine and comorbidities in patients receiving casirivimab-imdevimab monoclonal antibody during SARS-CoV-2 B.1.617.2 (Delta) surge: A real-world study.
    Agrawal P; Damania D; Cseh A; Grab J; Strom L; Frank B; Patel D; Clyatt G
    Vaccine; 2023 Aug; 41(35):5195-5200. PubMed ID: 37451874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
    Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
    Front Immunol; 2021; 12():790469. PubMed ID: 34956222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
    JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual Monoclonal Antibodies on Sars-Cov-2 Alpha and Delta Variants: Clinical and Virological Efficacy.
    Ferré VM; Peiffer-Smadja N; Kramer L; Coppée R; Kante A; Debarge M; Choquet C; Saint Joannis T; Bouzid D; Messika J; Le Grand J; Thy M; Kernéis S; Descamps D; Visseaux B; Ghosn J
    Microbiol Spectr; 2022 Oct; 10(5):e0215222. PubMed ID: 36125289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving Real-World Effectiveness of Monoclonal Antibodies for Treatment of COVID-19 : A Cohort Study.
    Kip KE; McCreary EK; Collins K; Minnier TE; Snyder GM; Garrard W; McKibben JC; Yealy DM; Seymour CW; Huang DT; Bariola JR; Schmidhofer M; Wadas RJ; Angus DC; Kip PL; Marroquin OC
    Ann Intern Med; 2023 Apr; 176(4):496-504. PubMed ID: 37011399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital.
    Keshishian E; Kuge E; Memmott J; Hasenbalg P; Belford N; Matlock A; Schritter S; Agbayani G; Dietrich T; Santarelli A; Ashurst J
    J Osteopath Med; 2022 Dec; 122(12):635-640. PubMed ID: 36123325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy of casirivimab-imdevimab antibody combination treatment in patients with COVID-19 Delta variant.
    Miyashita N; Nakamori Y; Ogata M; Fukuda N; Yamura A; Ishiura Y
    J Infect Chemother; 2022 Sep; 28(9):1344-1346. PubMed ID: 35637130
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
    Dougan M; Nirula A; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Dabora MC; Klekotka P; Shen L; Skovronsky DM;
    N Engl J Med; 2021 Oct; 385(15):1382-1392. PubMed ID: 34260849
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characterization of Casirivimab Plus Imdevimab, Sotrovimab, and Bamlanivimab Plus Etesevimab-Derived Interference in Serum Protein Electrophoresis and Immunofixation Electrophoresis.
    Scholl AR; Korentzelos D; Forns TE; Brenneman EK; Kelm M; Datto M; Wheeler SE; Carlsen ED
    J Appl Lab Med; 2022 Oct; 7(6):1379-1387. PubMed ID: 35993812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
    Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
    Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort.
    Soria A; Graziano F; Ghilardi G; Lapadula G; Gasperina DD; Benatti SV; Quiros-Roldan E; Milesi M; Bai F; Merli M; Minisci D; Franzetti M; Asperges E; Chiabrando F; Pocaterra D; Pandolfo A; Zanini F; Lombardi D; Cappelletti A; Rugova A; Borghesi ML; Squillace N; Pusterla L; Piconi S; Morelli P; Querini PR; Bruno R; Rusconi S; Casari S; Bandera A; Franzetti F; Travi G; D'Arminio Monforte A; Marchetti G; Pan A; Castelli F; Rizzi M; Dentali F; Mallardo M; Rossi E; Valsecchi MG; Galimberti S; Bonfanti P
    Heliyon; 2024 Aug; 10(16):e36102. PubMed ID: 39247344
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?
    Doggrell SA
    Expert Opin Biol Ther; 2021 Nov; 21(11):1359-1362. PubMed ID: 34555986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet; 2022 Feb; 399(10325):665-676. PubMed ID: 35151397
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19.
    Zou J; Jing F
    Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Monoclonal Antibodies in Pregnant Women Infected by COVID-19: A Case Series.
    Crispino P; Marocco R; Di Trento D; Guarisco G; Kertusha B; Carraro A; Corazza S; Pane C; Di Troia L; Del Borgo C; Lichtner M
    Microorganisms; 2023 Jul; 11(8):. PubMed ID: 37630512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single Site Experience of the use of Monoclonal Antibodies for the Treatment of COVID-19 in High-risk Pediatric and Young Adult Patients.
    Bahakel H; Murphy C; Frenck RW; Grimley MS; Marsh RA; Paulsen GC; Haslam DB; Phillips CL; Courter J; Spearman P; Schulert G; Danziger-Isakov L
    Pediatr Infect Dis J; 2022 Dec; 41(12):985-988. PubMed ID: 36219876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge.
    Bierle DM; Ganesh R; Razonable RR
    J Clin Virol; 2021 Dec; 145():105026. PubMed ID: 34775142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful early use of anti-SARS-CoV-2 monoclonal neutralizing antibodies in SARS-CoV-2 infected hematological patients - A Czech multicenter experience.
    Weinbergerová B; Demel I; Víšek B; Válka J; Čerňan M; Jindra P; Novák J; Stejskal L; Kovácsová F; Kabut T; Szotkowski T; Hájek R; Žák P; Cetkovský P; Král Z; Mayer J
    Hematol Oncol; 2022 Apr; 40(2):280-286. PubMed ID: 35120267
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
    Dougan M; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Blomkalns A; Adams AC; Van Naarden J; Custer KL; Knorr J; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Sabo J; Patel DR; Dabora MC; Williams M; Klekotka P; Shen L; Skovronsky DM; Nirula A
    Clin Infect Dis; 2022 Aug; 75(1):e440-e449. PubMed ID: 34718468
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.